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abstract
Background: Iloprost, a stable prostacyclin analog, is used 
as a rescue therapy for severe peripheral arterial disease 
(PAD). It has systemic vasodilatory and anti-aggregant 
effects, with severe vasodilatation potentially causing organ 
ischaemia when severe atherosclerosis is the underlying cause. 
In this study, we retrospectively analysed renal outcomes after 
iloprost infusion therapy in 86 patients.
Methods: Eighty-six patients with PAD who received iloprost 
infusion therapy were retrospectively analysed. Clinical and 
biochemical parameters were recorded before (initial, Cr1), 
during (third day, Cr2), and after (14th day following the 
termination of  infusion therapy, Cr3) treatment. Acute 
kidney injury (AKI) was defined according to KDIGO guide-
lines as a ≥ 0.3 mg/dl (26.52 μmol/l) increase in creatinine 
levels from baseline within 48 hours. 
Results: Cr2 (1.46 ± 0.1 mg/dl) (129.06 ± 8.84 μmol/l) and Cr3 
(1.53 ± 0.12 mg/dl) (135.25 ± 10.61 μmol/l) creatinine levels 
were significantly higher compared to the initial value (1.15 
± 0.6 mg/dl) (101.66 ± 53.04 μmol/l). AKI was observed in 
36 patients (41.86%) on the third day of iloprost infusion. 
Logistic regression analysis revealed smoking and not using 
acetylsalicylic acid as primary predictors (p = 0.02 and p = 
0.008, respectively) of AKI during iloprost treatment. On 
the third infusion day, patients’ urinary output significantly 
increased (1813.30 ± 1123.46 vs 1545.17 ± 873.00 cm3) and 
diastolic blood pressure significantly decreased (70.07 ± 15.50 
vs 74.14 ± 9.42 mmHg) from their initial values.
Conclusion: While iloprost treatment is effective in patients 
with PAD who are not suitable for surgery, severe systemic 
vasodilatation can cause renal ischaemia, resulting in non-
oliguric AKI. Smoking, no acetylsalicylic acid use, and lower 
diastolic blood pressure are the clinical risk factors for AKI 
during iloprost treatment.
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Iloprost is a stable epoprostenol (prostacyclin, PGI2) analog that 
mimics the effects of prostacyclin in the microvascular blood 
flow, namely, inhibition of platelet aggregation, leukocyte–vessel 
interaction and vasodilatation.1,2 A superior chemical stability 
confers iloprost with a longer half-life than that of prostacyclin, 
giving it an advantage as a therapeutic agent for the treatment 
of many cardiovascular and pulmonary diseases.3 Iloprost also 
inhibits platelet aggregation and leukocyte activation, and leads 
to vasodilatation in ischaemic tissue after ischaemia/reperfusion 
(I/R) injury.4,5 Iloprost is used as a rescue therapy for patients 
with severe obstructive peripheral arterial disease (PAD) who 
cannot tolerate surgery.
Renoprotective effects of iloprost have been reported in 
contrast-induced nephropathy and I/R injury.6 In these cases, 
iloprost infusion was administered either at a low dose or 
for a short duration, causing vasodilation without systemic 
hypotension.7,8 On the other hand, during rescue therapy for 
severe atherosclerosis, its use may lower blood pressure,9 leading 
to tissue ischaemia, renal hypoperfusion and acute kidney injury.10
Because of iloprost’s hypotension-inducing potent systemic 
vasodilatory effect, several potential safety issues should 
be considered in these patients.11 This ischaemia-triggering 
hypoperfusion effect of iloprost may cause organ dysfunction, 
such as acute kidney injury, especially in patients with 
co-morbidities. On the basis of the systemic hypotensive effect of 
iloprost and our clinical experience of patients with acute kidney 
injury under iloprost treatment, we retrospectively analysed the 
effects of iloprost infusion therapy on renal outcomes in 86 
patients.
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methods
We retrospectively analysed patients with severe PAD who 
received iloprost infusion therapy at a dose of 1 ng/kg/min between 
January 2011 and January 2012 at Baskent University Hospital, 
Ankara, Turkey. Severe PAD was detected with non-invasive 
tests, including ankle–brachial index < 0.40 and absent blood flow 
on duplex ultasonography. Among these, 86 patients were selected 
according to the following exclusion criteria: (1) malignant 
disease, (2) rheumatological or chronic inflammatory disease of 
unknown origin, (3) history of systemic vasculitis, (4) unstable 
heart failure (ejection fraction < 50%) during infusion therapy, 
(5) chronic liver failure, (6) systemic infective or non-infective 
inflammatory diseases, (7) evidence of end-stage renal disease 
(ESRD), (8) younger than 18 years of age. An informed consent 
was obtained from all subjects of the study.
According to the treatment protocol, patients received iloprost 
infusion at a dose of 1 ng/kg/min for 10–14 days. Iloprost in a 
100-ml isotonic solution was infused during a six-hour period 
via the intravenous route. Nausea, flushing, headache and 
thrombophlebitis were recorded as drug-related side effects. 
In accordance with the Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines, acute kidney injury (AKI) was 
defined as ≥ 0.3 mg/dl (26.52 μmol/l) increase in creatinine levels 
from baseline within 48 hours.12 
The following parameters were collected retrospectively from 
clinical charts: (1) age; (2) gender; (3) smoking status; (4) 
presence of diabetes, hypertension, dyslipidaemia [serum high-
density lipoprotein cholesterol (HDL-C) < 40 mg/dl (1.04 
mmol/l) and/or low-density lipoprotein cholesterol (LDL-C) > 
130 mg/dl (3.37 mmol/l) and/or triglycerides > 300 mg/dl (3.39 
mmol/l)], or ischaemic heart disease; (4) urinary output; (5) use 
of statins, acetylsalicylic acid (ASA), clopidogrel, low-molecular-
weight heparin (LMWH), angiotensin converting enzyme 
inhibitors (ACEI), or angiotensin receptor blockers (ARB); 
(6) daily systolic, diastolic and mean arterial (2 × diastolic 
pressure + systolic pressure)/3) blood pressure measurement 
data; (7) haemoglobin, sodium, potassium, calcium, phosphorus, 
albumin, blood urea nitrogen (BUN), creatinine, and estimated 
glomerular filtration rate (eGFR) (MDRD equation) values.
Clinical and biochemical parameters were collected before 
(baseline), during (third day of infusion therapy) and after (two 
weeks after cessation of infusion therapy; 28th day) iloprost 
treatment, and mean values were determined as arithmetic 
means. Baseline values were defined as those measured at 
admission to the in-patient clinic. Office blood pressure levels 
were recorded.
Statistical analysis
Statistical analyses were performed using SPSS software 
(Statistical Package for the Social Sciences, version 15.0, SPSS 
Inc, Chicago, IL, USA). Subjects were grouped according to the 
absence of AKI, as the normal renal function group (n = 50), and 
presence of AKI, as the AKI group (n = 36). 
Normality of data was analysed using the Kolmogorov–
Smirnov test. All numerical variables with normal distributions 
were expressed as means ± standard deviations (SD), while 
variables with skewed distributions were expressed as medians and 
interquartile ranges (IR). Categorical variables were expressed as 
percentages and compared using the chi-squared test. Normally 
distributed numerical variables were analysed by the independent 
samples t-test, one-way ANOVA (post-hoc Tukey), or paired 
samples t-test. Numerical variables with a skewed distribution 
were compared using the Mann–Whitney U- and Kruskal–
Wallis tests. Spearman and Pearson correlation tests were used 
for correlation analyses. A binary logistic regression analysis 
was performed to assess the major determinant of AKI between 
correlated variables. A Kaplan–Meier survival analysis was used 
table 1. Clinical features of the patients
Whole study 
group  
(n = 86)
Patients 
with AKI  
(n = 36)
Patients 
without AKI 
(n = 50) p-value
Age (years) 65.82 ± 16.7 69.77 ± 12.9 64.24 ± 17.0 0.109
Male gender, n (%) 56 (66.2) 21 (58.3) 35 (70) 0.186
Diabetes mellitus, n (%) 48 (55.8) 22 (61.1) 26 (52) 0.221
Hypertension, n (%) 84 (97.6) 36 (100) 48 (96) 0.196
Ischaemic heart disease, n (%) 40 (46.5) 17 (47.2) 23 (46) 0.542
Dyslipidaemia, n (%) 24 (27.9) 10 (27.8) 14 (28) 0.589
Smoking habbit, n (%) 43 (50) 14 (38.9) 29 (58) 0.063
ASA, n (%) 57 (66.2) 20 (55.6) 37 (74) 0.045
Clopidogrel, n (%) 26 (30.2) 12 (33.3) 14 (28) 0.340
LMWH, n (%) 43 (50) 16 (44.4) 27 (54) 0.265
Statin, n (%) 18 (20.9) 8 (22.2) 10 (20) 0.354
ACEI, n (%) 32 (37.2) 14 (38.9) 18 (36) 0.469
ARB, n (%) 5 (5.8) 2 (5.5) 3 (6) 0.657
Mortality rate at 30 days’ 
follow up, n (%)
9 (10.4) 8 (22.2) 1 (2) 0.003
ASA, acetylsalicylic acid; LMWH, low-molecular-weight heparin; ACEI, angio-
tensin converting enzyme inhibitors; ARB, angiotensin receptor blocker. 
table 2. the laboratory parameters of the whole study group
Laboratory  
parameters Initial
Third day of 
infusion
Two weeks after 
infusion p-value
Glucose (mg/dl)
(mmol/l)
143.9 ± 69.7
(7.99 ± 3.87)
135.65 ± 49.39
(7.53 ± 2.74)
141.55 ± 66.2
(7.86 ± 3.67)
0.062*
0.289§
BUN (mg/dl) 23.6 ± 13.7 30.0 ± 20.7 24.9 ± 13.5 0.014*
0.458§
Creatinine (mg/dl)
(μmol/l)
1.15 ± 0.60
(101.66 ± 53.04)
1.53 ± 0.12 
(135.25 ± 10.61)
1.46 ± 0.10
(129.06 ± 8.84)
0.001*
0.001§
Haemoglobin (g/dl) 12.7 ± 2.1 11.8 ± 1.9 11.7 ± 1.6 0.236*§
Sodium (mmol/l) 134.9 ± 14.8 137.4 ± 4.9 137.1 ± 15.7 0.228*
0.117§
Potassium (mmol/l) 4.76 ± 0.78 4.11 ± 0.68 4.42 ± 0.92 0.406*
0.606§
Phosphorus
(mg/dl)
3.45 ± 0.78 3.80 ± 2.18 3.87 ± 1.38 0.865*
0.185§
Calcium (mg/dl) 8.9 ± 0.6 8.8 ± 0.8 8.9 ± 1.4 0.307*
0.587§
Albumin (g/dl) 3.6 ± 0.7 3.4 ± 0.8 3.2 ± 0.7 0.339*
0.047§
CRP (mg/dl) 52.48 ± 4.85 81.12 ± 4.67 67.05 ± 5.15 0.009*
0.125§
Urinary output 
(cm3/24 h)
1545.17 ± 873.00 1813.30 ± 1123.46 1447.32 ± 934.63 0.012*
0.406§
eGFR (MDRD)
(ml/min/1.73 m2)
76.98 ± 35.57 71.16 ± 43.43 72.84 ± 53.39 0.01*
0.04§
Systolic blood pres-
sure (mmHg)
122.97 ± 16.51 118.16 ± 26.41 121.71 ± 19.72 0.606*
0.117§
Diastolic blood 
pressure (mmHg)
74.37 ± 9.09 70.29 ± 14.94 71.20 ± 12.65 0.011*
0.025§
Mean arterial pres-
sure (mmHg)
90.57 ± 10.5 86.25 ± 17.9 88.04 ± 14.3 0.024*
0.112
*p-value for initial vs at the third day of infusion; §p-value for initial vs two weeks 
after infusion.
BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR, estimated glomerular 
filtration rate.
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to compare 30-day patient survival between the two groups. A 
p-value < 0.05 was considered statistically significant.
results
The clinical features of the patients are summarised in Table 
1. According to KDIGO criteria, 36 (41.86%) patients were 
diagnosed with AKI on the third day of iloprost infusion therapy. 
Co-morbidities and drug use (ASA, clopidogrel, LMWH, statin, 
ACEI) rates were similar in those with and without AKI (Table 1). 
When the entire study group was analysed, serum creatinine 
levels recorded on the third and 28th day of treatment (1.53 
± 0.12 and 1.46 ± 0.1 mg/dl, respectively) (135.25 ±10.61 and 
129.06 ± 8.84 μmol/l) were significantly higher than the baseline 
level [1.15 ± 0.6 mg/dl (101.66 ± 53.04 μmol/l), p = 0.001 for 
both]. The BUN level recorded on the third day (30.0 ± 20.7 mg/
dl) was significantly higher than the baseline level (23.6 ± 13.7 
mg/dl, p = 0.014), as was the serum C-reactive protein (CRP) 
level (81.12 ± 4.67 vs 52.48 ± 4.85 mg/dl, p = 0.009). On the third 
day of the infusion, urinary output was significantly increased 
from the baseline value (1 813.30 ± 1 123.46 vs 1 545.17 ± 873.0 
cm3, p = 0.012) while eGFR values were significantly lower 
compared to baseline levels (71.16 ± 43.43 vs 76.98 ± 35.57 ml/
min/1.73 m2, p = 0.01) (Table 2). All patients had a significant 
decrease from baseline in diastolic blood pressure on the third 
day of infusion therapy (70.29 ± 14.94 vs 74.37 ± 9.09 mmHg, 
p = 0.011). Patients’ mean arterial pressures were significantly 
decreased on the third day of therapy (90.57 ± 10.5 vs 86.25 ± 
17.9 mmHg, p = 0.024). 
On the 28th day, eGFR values were significantly lower than 
baseline values (72.84 ± 53.39 vs 76.98 ± 35.57 ml/min/1.73 m2, 
p = 0.01) (Table 2). All patients had a significant decrease in 
diastolic blood pressure on the 28th day compared to baseline 
values (71.20 ± 12.65 vs 74.37 ± 9.09 mmHg, p = 0.025). A 
non-significant trend towards a lower blood pressure on the third 
and 28th days was observed (p > 0.05) (Table 2). According to 
data from the 28th day, renal function improved as BUN levels 
decreased to baseline values, while the creatinine level was high 
and eGFR was significantly lower (Table 2). 
Patients who developed AKI had significantly higher 
serum creatinine (p = 0.032) and CRP (p = 0.012) levels and 
significantly lower eGFR values (p = 0.05) at baseline compared 
to patients without AKI (Table 3). Those who developed AKI 
had significantly higher serum BUN (p = 0.001) and creatinine 
(p = 0.001) levels and lower eGFR (p = 0.001) and systolic (p = 
0.015), diastolic (p = 0.014) and mean arterial (p = 0.039) blood 
pressure values on the third day of infusion compared to patients 
without AKI (Table 3). 
Serum glucose levels of patients with AKI were significantly 
higher both compared to their own baseline value (p = 0.042) and 
to the value of the third day of patients without AKI (p = 0.037) 
(Table 3). Patients who developed AKI had significantly higher 
serum creatinine (p = 0.001), BUN (p = 0.012), CRP (p = 0.001) 
and urinary output (p = 0.005) levels on the third day of infusion 
table 3. laboratory parameters of the whole group
Laboratory  
parameters
Initial Third day of infusion Two weeks after infusion p-values 
within 
the AKI 
group
Patients with 
AKI (n = 36)
Patients without 
AKI (n = 50) p-value
Patients with 
AKI (n = 36)
Patients without 
AKI (n = 50) p-value
Patients with 
AKI (n = 36)
Patients without 
AKI (n = 50) p-value
Glucose (mg/dl)
(mmol/l)
146.32 ± 67.9
(8.12 ± 3.77)
141.21 ± 72.3 
(7.84 ± 4.01)
> 0.05 120.46 ± 41.7
(6.69 ± 2.31)
146.20 ± 47.3 
(8.11 ± 2.63)
0.037 133.17 ± 61.3
(7.39 ± 3.40)
147.10 ± 72.0
(8.16 ± 4.00) 
> 0.05 0.042*
> 0.05§†
BUN (mg/dl) 26.0 ± 12.1 22.4 ± 14.7 > 0.05 44.88 ± 21.6 19.40 ± 8.28 0.001 33.08 ± 15.5 18.4 ± 9.1 0.001 0.012*
0.001§†
Creatinine (mg/dl)
(μmol/l)
1.28 ± 0.60
(113.15 ± 53.04)
1.05 ± 0.5 
(92.82 ± 44.20)
0.032 2.37 ± 1.26
(209.51 ± 111.38)
0.94 ± 0.3
(83.10 ± 26.52)
0.001 2.14 ± 1.11
(189.18 ± 98.12)
0.87 ± 0.3
(76.91 ± 26.52)
0.001 0.001*
> 0.05§
0.001†
Haemoglobin (g/dl) 12.09 ± 2.1 13.04 ± 2.0 > 0.05 11.33 ± 1.8 12.06 ± 1.8 > 0.05 11.88 ± 1.1 12.30 ± 1.6 > 0.05 > 0.05*§†
Sodium (mmol/l) 136.91 ± 4.0 133.74 ± 19.1 > 0.05 138.05 ± 6.2 136.91 ± 3.4 > 0.05 139.16 ± 5.6 135.20 ± 20.3 > 0.05 > 0.05*§†
Potassium (mmol/l) 4.34 ± 0.5 4.19 ± 0.9 > 0.05 4.17 ± 0.6 4.07 ± 0.7 > 0.05 4.16 ± 0.8 4.17 ± 0.2 > 0.05 > 0.05*§†
Phosphorus
(mg/dl)
3.72 ± 0.8 3.22 ± 0.6 > 0.05 4.28 ± 2.9 3.28 ± 0.5 > 0.05 4.60 ± 1.6 3.23 ± 0.7 > 0.05 > 0.05*§†
Calcium (mg/dl) 8.84 ± 0.5 8.93 ± 0.7 > 0.05 8.98 ± 1.09 8.67 ± 0.6 > 0.05 9.21 ± 1.9 8.78 ± 0.7 > 0.05 > 0.05*§†
Albumin (g/dl) 3.53 ± 0.6 3.73 ± 0.8 > 0.05 2.62 ± 1.0 3.42 ± 0.6 > 0.05 2.91 ± 0.7 3.62 ± 0.6 0.001 > 0.05*§†
CRP (mg/dl) 67.62 ± 7.7 40.38 ± 4.3 0.012 102.85 ± 9.7 70.67 ± 6.6 0.012 90.62 ± 8.7 52.80 ± 9.3 > 0.05 0.001*
> 0.05§
0.01†
Urinary output 
(cm3/24 h)
1242.91 ± 990.15 1663.37 ± 736.3 > 0.05 1503.20 ± 1267.09 1918.18 ± 827.1 0.004 1259.63 ± 986.0 1632.96 ± 648.2 > 0.05 0.005*§
> 0.05†
eGFR (MDRD) 70.22 ± 41.7 84.83 ± 34.3 0.05 36.04 ± 23.4 93.10 ± 40.2 0.001 40.68 ± 25.9 101.03 ± 52.84 0.001 0.0001*†
> 0.05§
Systolic blood pres-
sure (mmHg)
121.6 ± 19.5 123.78 ± 14.5 > 0.05 106.8 ± 31.7 125.0 ± 10.8 0.015 116.2 ± 28.6 124.92 ± 20.1 > 0.05 0.002*
> 0.05§
0.023†
Diastolic blood 
pressure (mmHg)
71.8 ± 10.5 75.90 ± 7.8 > 0.05 61.2 ± 17.5 74.64 ± 8.2 0.014 65.4 ± 16.4 75.71 ± 9.9 0.001 0.023*
> 0.05§
0.002†
Mean arterial pres-
sure (mmHg)
88.40 ± 12.5 91.86 ± 8.9 > 0.05 76.0 ± 21.6 91.42 ± 8.0 0.039 82.36 ± 19.9 92.11 ± 12.1 0.002 0.003*
> 0.05§
0.04†
*p-value for initial vs on the third day of infusion; §p-value for initial vs two weeks after infusion; †p-value for third day vs two weeks after infusion.  
BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
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compared to baseline values. Among patients who developed 
AKI, systolic (p = 0.002), diastolic (p = 0.023) and mean arterial 
pressures (p = 0.003) as well as eGFR (p = 0.0001) values were 
significantly lower on the third day of infusion compared to the 
baseline value (Table 3). 
Drug-related side effects were similar in both patient groups 
(Table 4). A binary logistic regression analysis of co-morbidities 
and drugs revealed that smoking, diastolic hypotension, and no 
ASA use were significant independent predictors (p = 0.02, p = 
0.003 and p = 0.008, respectively) for the development of AKI 
during iloprost treatment. 
We also evaluated factors associated with 30-day mortality 
and compared survival ratios between the patient groups. The 
Cox regression analysis revealed that diabetes mellitus (p = 0.005) 
and AKI (p = 0.012) are significant determinants of mortality 
in patients undergoing iloprost infusion therapy. The Kaplan–
Meier analysis revealed a significant difference in survival 
between patients with AKI and those without AKI (at 30-day 
follow up: 22.2 vs 2%, p = 0.001) (Fig. 1). 
discussion
AKI refers to a rapid and reversible decrease in kidney 
function that develops within a period of hours or days. In 
this retrospective study, we assessed the relationship between 
laboratory and clinical parameters and subsequent changes in 
kidney function in patients with PAD who developed AKI after 
iloprost infusion therapy. 
We observed that iloprost infusion therapy led to hypotension 
(systolic, diastolic and mean arterial pressure) and a significant 
decline in eGFR. Patients who developed AKI were more likely 
to have worse renal function at the initiation of therapy than 
other patients. In the multivariate analysis, diastolic hypotension, 
smoking and lack of  ASA treatment were independently 
associated with an increased risk of developing AKI. In addition, 
AKI was associated with a higher mortality rate at the 30-day 
follow up.
In the kidney, prostaglandins uphold the balance between 
vasodilation and vasoconstriction to maintain homeostasis and 
physiological kidney function.13,14 Vasodilator prostaglandins 
have clinically important side effects that underscore their 
potential efficacy in the treatment of severe PAD.15 
In experimental animal studies, iloprost preserved kidney 
function against anoxia in rabbits,16 and had beneficial effects 
in I/R-induced renal injury in a rat model.17 Furthermore, in a 
clinical study by Spargias et al., iloprost was successfully used 
to prevent contrast-mediated nephropathy.9 However, in these 
studies that reported iloprost to be a renoprotective agent, the 
selected doses were as low as 1–2 ng/kg/min and the infusion 
period lasted approximately four to six hours to avoid systemic 
hypotension, and dosing was not repeated.9,17-19 
Hypotension is the principal, dose-dependent side effect of 
iloprost. There is evidence that such hypotension is a risk factor 
for the development of AKI and it is a commonly encountered 
problem in elderly patients with AKI,20-22 patients with pre-existing 
renal insufficiency,23,24 and patients with low cardiac output states 
such as myocardial infarction and congestive cardiac failure.24-26 
We observed that patients who received iloprost had a 
significant decrease in systolic, diastolic and mean arterial 
pressure compared to baseline, and that relative diastolic 
hypotension was a significant risk factor for the development of 
AKI. In their study, Liu et al. showed an independent association 
between the relative decrease in systolic blood pressure and the 
development of AKI.27 Sutton et al.28 used an ischaemic rat 
model to demonstrate that the ‘initiation’ phase of AKI, during 
which renal blood flow is reduced, is the primary determinant 
of GFR.6 Similarly to these studies, our AKI patients had 
significantly lower diastolic blood pressure, causing decreased 
renal blood flow and leading to a decline in GFR.
In patients with chronic kidney disease (CKD), the risk of 
developing AKI is significantly increased.29 Co-morbidities such 
as diabetes, hypertension and proteinuria in hospitalised patients 
were independently associated with an increased risk of AKI, 
requiring dialysis.29,30 Our patients with AKI showed significantly 
reduced renal function with significantly higher serum creatinine 
levels and lower eGFR at the initiation of iloprost treatment. 
These patients were more prone to develop AKI because of the 
kidney’s sensitivity to disrupted microperfusion or hypotensive 
ischaemia. 
Consistent with these findings, smoking and the lack of ASA 
use were significant independent predictors for the development 
of AKI in our patients. Smoking is a major preventable risk 
factor for atherosclerosis. Exposure to cigarette smoke activates a 
number of mechanisms predisposing to atherosclerosis, including 
thrombosis, vascular inflammation, abnormal vascular growth 
and angiogenesis.31-33 
ASA, the fundamental therapy given for PAD, reduces the 
risk of cardiovascular events and arterial occlusion. The use of 
ASA for primary and secondary prevention of cardiovascular 
events in most patients with PAD is supported by excellent 
clinical evidence.34 Based on these data, we can speculate that the 
presence of smoking and absence of ASA use were associated 
with microvascular ischaemia, which made these patients more 
prone to hypotensive AKI. 
The mortality rate in AKI patients with CKD was 3.3 times 
higher than that of patients without CKD.35 In our study, 
patients with AKI had significantly higher mortality rates over 
table 4. drug-related side effects 
Side effects
Patients with AKI  
(n = 36)
Patients without AKI 
(n = 50) p-value
Nausea, n (%) 9 (25) 3 (6) 0.172
Flushing, n (%) 1 (2.7) 1 (2) 0.660
Headache, n (%) 1 (2.7) 3 (6) 0.448
Thrombophylebitis, n (%) 0 0 NA
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Fig. 1.  The Kaplan–Meier survival analysis between patients 
with AKI and those without AKI (at 30-day follow up: 
22.2 vs 2%, p = 0.001).
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30 days of follow up. In addition, according to our findings, 
diabetes mellitus and AKI were significant determinants of 
mortality in patients undergoing iloprost infusion therapy.
This study has several limitations, many of which are inherent 
in its retrospective design, including the possibility of missing 
risk factors that could contribute to a confounding bias. In 
addition, renal imaging studies were unavailable for all patients. 
However, the association between iloprost-induced hypotension 
and AKI was independent and clear. Our results clearly illustrate 
that relative hypotension may play a key role in the development 
of AKI during iloprost infusion therapy in patients with altered 
renal function. 
Conclusion
We conducted a retrospective study to evaluate the risk factors 
for AKI development and mortality in patients with severe PAD 
treated with iloprost. We found that patients who developed 
AKI were more likely to have relative decreases in systolic, 
diastolic and mean arterial pressures and worse baseline renal 
function than unaffected patients. We suggest that patients with 
a smoking habit and those not using ASA are at an increased 
risk for AKI. In this group of patients we advise iloprost 
dose reduction and close follow up for evidence of AKI, and 
discontinuation of iloprost in patients with severe hypotension. 
As patients with AKI have a higher mortality risk, we suggest 
that iloprost treatment should be given to selected patients. 
From our findings, we advise that iloprost should be avoided as 
it is very likely to cause AKI in patients with CKD or low blood 
pressure. In addition, we recommend iloprost dose reduction 
or possible discontinuation for patients receiving iloprost who 
show evidence of AKI or hypotension. Ultimately, prospective, 
randomised studies will be needed to address the effects of 
iloprost infusion therapy on renal outcomes in patients with 
severe PAD.
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